Colorectal cancer screening

A guide to the guidelines

Viju P. Deenadayalu, Douglas Rex

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The best known guidelines for colorectal cancer screening in the United States are those of the US Multisociety Task Force on Colorectal Cancer, the American Cancer Society, the United States Preventive Services Task Force, the American College of Gastroenterology, and the American Society of Gastrointestinal Endoscopy. Screening is currently endorsed for both average-risk and high-risk persons by all guideline groups. Some guidelines offer a menu of options for average-risk persons, from which patients and physicians can select according to their perceptions and values regarding effectiveness, risk, and upfront costs. The alternative approach of colonoscopy as the preferred strategy simplifies discussions with patients and better reflects current trends in procedure use in the United States. For patients who refuse invasive testing, fecal occult blood testing is available. Quantitative fecal immunochemical tests offer promise for improved performance compared with guaiac testing. Radiographic screening has declined, although double contrast barium enema still remains an option in some guidelines. Computed tomographic colonography remains under active consideration but is not yet endorsed by any of the guidelines. High risk is still based primarily on family history, and the guidelines are fairly consistent in adjusting screening modality and intervals according to family history.

Original languageEnglish
Pages (from-to)204-213
Number of pages10
JournalReviews in Gastroenterological Disorders
Volume7
Issue number4
StatePublished - Sep 2007

Fingerprint

Early Detection of Cancer
Colorectal Neoplasms
Guidelines
Advisory Committees
Guaiac
Computed Tomographic Colonography
Occult Blood
Gastrointestinal Endoscopy
Colonoscopy
Physicians
Costs and Cost Analysis

Keywords

  • Colonoscopy
  • Colorectal cancer
  • Double contrast barium enema
  • Familial adenomatous polyposis
  • Fecal occult blood test
  • Flexible sigmoidoscopy
  • Hereditary nonpolyposis colorectal cancer
  • Screening

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Colorectal cancer screening : A guide to the guidelines. / Deenadayalu, Viju P.; Rex, Douglas.

In: Reviews in Gastroenterological Disorders, Vol. 7, No. 4, 09.2007, p. 204-213.

Research output: Contribution to journalArticle

Deenadayalu, VP & Rex, D 2007, 'Colorectal cancer screening: A guide to the guidelines', Reviews in Gastroenterological Disorders, vol. 7, no. 4, pp. 204-213.
Deenadayalu, Viju P. ; Rex, Douglas. / Colorectal cancer screening : A guide to the guidelines. In: Reviews in Gastroenterological Disorders. 2007 ; Vol. 7, No. 4. pp. 204-213.
@article{8746c38fedf042d0bc58d63773f84fbd,
title = "Colorectal cancer screening: A guide to the guidelines",
abstract = "The best known guidelines for colorectal cancer screening in the United States are those of the US Multisociety Task Force on Colorectal Cancer, the American Cancer Society, the United States Preventive Services Task Force, the American College of Gastroenterology, and the American Society of Gastrointestinal Endoscopy. Screening is currently endorsed for both average-risk and high-risk persons by all guideline groups. Some guidelines offer a menu of options for average-risk persons, from which patients and physicians can select according to their perceptions and values regarding effectiveness, risk, and upfront costs. The alternative approach of colonoscopy as the preferred strategy simplifies discussions with patients and better reflects current trends in procedure use in the United States. For patients who refuse invasive testing, fecal occult blood testing is available. Quantitative fecal immunochemical tests offer promise for improved performance compared with guaiac testing. Radiographic screening has declined, although double contrast barium enema still remains an option in some guidelines. Computed tomographic colonography remains under active consideration but is not yet endorsed by any of the guidelines. High risk is still based primarily on family history, and the guidelines are fairly consistent in adjusting screening modality and intervals according to family history.",
keywords = "Colonoscopy, Colorectal cancer, Double contrast barium enema, Familial adenomatous polyposis, Fecal occult blood test, Flexible sigmoidoscopy, Hereditary nonpolyposis colorectal cancer, Screening",
author = "Deenadayalu, {Viju P.} and Douglas Rex",
year = "2007",
month = "9",
language = "English",
volume = "7",
pages = "204--213",
journal = "Reviews in Gastroenterological Disorders",
issn = "1533-001X",
publisher = "MedReviews LLC",
number = "4",

}

TY - JOUR

T1 - Colorectal cancer screening

T2 - A guide to the guidelines

AU - Deenadayalu, Viju P.

AU - Rex, Douglas

PY - 2007/9

Y1 - 2007/9

N2 - The best known guidelines for colorectal cancer screening in the United States are those of the US Multisociety Task Force on Colorectal Cancer, the American Cancer Society, the United States Preventive Services Task Force, the American College of Gastroenterology, and the American Society of Gastrointestinal Endoscopy. Screening is currently endorsed for both average-risk and high-risk persons by all guideline groups. Some guidelines offer a menu of options for average-risk persons, from which patients and physicians can select according to their perceptions and values regarding effectiveness, risk, and upfront costs. The alternative approach of colonoscopy as the preferred strategy simplifies discussions with patients and better reflects current trends in procedure use in the United States. For patients who refuse invasive testing, fecal occult blood testing is available. Quantitative fecal immunochemical tests offer promise for improved performance compared with guaiac testing. Radiographic screening has declined, although double contrast barium enema still remains an option in some guidelines. Computed tomographic colonography remains under active consideration but is not yet endorsed by any of the guidelines. High risk is still based primarily on family history, and the guidelines are fairly consistent in adjusting screening modality and intervals according to family history.

AB - The best known guidelines for colorectal cancer screening in the United States are those of the US Multisociety Task Force on Colorectal Cancer, the American Cancer Society, the United States Preventive Services Task Force, the American College of Gastroenterology, and the American Society of Gastrointestinal Endoscopy. Screening is currently endorsed for both average-risk and high-risk persons by all guideline groups. Some guidelines offer a menu of options for average-risk persons, from which patients and physicians can select according to their perceptions and values regarding effectiveness, risk, and upfront costs. The alternative approach of colonoscopy as the preferred strategy simplifies discussions with patients and better reflects current trends in procedure use in the United States. For patients who refuse invasive testing, fecal occult blood testing is available. Quantitative fecal immunochemical tests offer promise for improved performance compared with guaiac testing. Radiographic screening has declined, although double contrast barium enema still remains an option in some guidelines. Computed tomographic colonography remains under active consideration but is not yet endorsed by any of the guidelines. High risk is still based primarily on family history, and the guidelines are fairly consistent in adjusting screening modality and intervals according to family history.

KW - Colonoscopy

KW - Colorectal cancer

KW - Double contrast barium enema

KW - Familial adenomatous polyposis

KW - Fecal occult blood test

KW - Flexible sigmoidoscopy

KW - Hereditary nonpolyposis colorectal cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=37849034567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849034567&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 204

EP - 213

JO - Reviews in Gastroenterological Disorders

JF - Reviews in Gastroenterological Disorders

SN - 1533-001X

IS - 4

ER -